UPDATED May 06, 2024
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
GTHX | US$4.25 | 12.7% | 44.1% | US$223.2m | US$8.50 | PS2.6x | E48.2% | n/a | Pharmaceuticals & Biotech | ||
ACTD | US$7.79 | -24.2% | -21.2% | US$303.0m | US$17.00 | PE-25.3x | E85.2% | n/a | Diversified Financials | ||
AZ | US$0.38 | -7.6% | -71.6% | US$20.8m | US$18.00 | PS1.7x | E75.4% | n/a | Capital Goods | ||
LICY | US$0.66 | 0.6% | -87.0% | US$129.1m | n/a | PS6.4x | E60.1% | n/a | Commercial Services | ||
SONM | US$0.54 | 3.2% | -42.2% | US$24.2m | US$2.00 | PB1.1x | E139.9% | n/a | Tech | ||
ZYNE | US$1.30 | 4.0% | 96.1% | US$65.6m | US$1.26 | PB2.3x | E67.2% | n/a | Pharmaceuticals & Biotech | ||
ZVRA | US$5.18 | 13.0% | 16.8% | US$215.7m | US$19.00 | PS7.9x | E63.6% | n/a | Pharmaceuticals & Biotech | ||
CKPT | US$1.69 | 21.6% | -39.2% | US$58.2m | US$17.25 | PS585.5x | E88.1% | n/a | Pharmaceuticals & Biotech | ||
GMED | US$51.36 | 3.2% | -9.3% | US$6.8b | US$65.31 | PE56.5x | E31.3% | n/a | Healthcare | ||
IREN | US$5.07 | 16.8% | 33.4% | US$747.8m | US$11.00 | PS5.8x | E110.2% | n/a | Software | ||
AQMS | US$0.49 | 4.5% | -55.5% | US$56.7m | US$3.00 | PS2218.3x | E63.4% | n/a | Commercial Services | ||
PGEN | US$1.38 | 4.5% | 9.5% | US$363.5m | US$9.00 | PS56x | E55.5% | n/a | Pharmaceuticals & Biotech | ||
AMPG | US$2.28 | -0.4% | -26.7% | US$22.2m | US$9.00 | PS1.4x | E107.0% | n/a | Tech | ||
XELB | US$0.77 | 2.4% | 18.1% | US$17.4m | US$3.00 | PS1x | E114.9% | n/a | Retail | ||
OCUP | US$1.94 | 22.4% | -66.6% | US$51.5m | US$19.50 | PS2.6x | E9.5% | n/a | Pharmaceuticals & Biotech | ||
MVST | US$0.42 | 7.9% | -67.7% | US$136.3m | US$4.67 | PB0.2x | E46.7% | n/a | Capital Goods | ||
PTGX | US$26.06 | 2.0% | 4.5% | US$1.5b | US$43.00 | PS25.5x | E50.0% | n/a | Pharmaceuticals & Biotech | ||
SCPH | US$4.90 | 9.6% | -56.5% | US$170.5m | US$19.50 | PS13x | E59.8% | n/a | Pharmaceuticals & Biotech | ||
PESI | US$12.11 | 5.8% | 39.4% | US$164.9m | US$19.00 | PE180.3x | E133.4% | n/a | Commercial Services | ||
VRCA | US$7.31 | 2.2% | 10.4% | US$310.1m | US$13.60 | PS60.5x | E61.6% | n/a | Pharmaceuticals & Biotech | ||
APLT | US$4.80 | 11.4% | 180.7% | US$548.4m | US$11.60 | PS54.9x | E81.9% | n/a | Pharmaceuticals & Biotech | ||
DTST | US$5.64 | 16.5% | 215.1% | US$38.2m | US$9.00 | PE102.3x | E65.4% | n/a | Software | ||
ATNM | US$8.81 | 14.4% | 4.4% | US$263.3m | US$25.47 | PS3239.4x | E68.3% | n/a | Pharmaceuticals & Biotech | ||
FTCI | US$0.53 | 19.2% | -79.8% | US$67.3m | n/a | PB1.1x | E63.1% | n/a | Capital Goods |